Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study

Table 4 Lipid alterations for DFS

Lipids	N (%)	Number of events	DFS (months), median and range	P value
Cholesterol^a				0.775
Elevation	93 (79.5)	55	33.10 (1.70-85.47)
Reduction	24 (20.5)	16	34.47 (0.70-81.17)
Triglyceride^a				0.949
Elevation	82 (70.1)	50	34.03 (0.70-85.47)
Reduction	35 (29.9)	21	30.20 (3.23–81.37)
HDL-C^a				0.0204
Elevation	92 (78.6)	60	26.12 (0.70-85.47)
Reduction	25 (21.4)	11	80.43 (10.53–81.17)
LDL-C^a				0.919
Elevation	84 (71.8)	50	31.22 (1.70-85.47)
Reduction	33 (28.2)	21	34.97 (0.70-81.17)
ApoA-I^a				0.286
Elevation	97 (82.9)	61	28.97 (0.70-85.47)
Reduction	20 (17.1)	10	80.43 (1.70-81.17)
ApoB^a				0.887
Elevation	81 (69.2)	49	33.10 (1.70-85.47)
Reduction	36 (30.8)	22	34.47 (0.70-81.17)

Data are mean ± standard deviations
Abbreviations: DFS disease free survival, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA-I apolipoprotein A-I, ApoB apolipoprotein B
^aComparison between lipids post-chemotherapy and lipids pre-chemotherapy

ISSN: 1476-511X